Tekla Healthcare Investors (HQH) Key Metrics
HQH valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $1.09B
- Enterprise value
- $1.06B
- P/E (TTM)
- 4.2 10-yr median 8.5
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 5.5 10-yr median 11.6
- Price / book
- 1.1 10-yr median 0.9
- EV / EBITDA
- — 10-yr median 9.0
- Dividend yield
- 13.01% $2.47 a year
- Beta
- 0.75
HQH key metrics, FY2016–FY2025
Fiscal year ended September 30, 2025 · U.S. dollarsHQH valuation Price multiples at each fiscal year-end price.
HQH returns How much profit the business earns on the capital it uses.
HQH per-share figures Results divided by the shares outstanding at year-end.
HQH financial health Debt, liquidity and how easily interest is covered.
HQH efficiency & capital use Working capital cycle and where the cash goes.
HQH valuation history
HQH returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
HQH debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
HQH price vs earnings per share
HQH key metrics
FY2016–FY2025| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $990.1M | $970.7M | $768.8M | $818.1M | $1.16B | $904.6M | $785.4M | $977.3M | $1.03B | $928.7M |
| Enterprise value | $990.1M | $970.7M | $768.8M | $826.6M | $1.17B | $902.2M | $783.8M | $977.3M | $1.02B | $928.7M |
| P/E ratio | 10.0 | 5.2 | 13.6 | — | 7.5 | 3.8 | — | 14.1 | 8.5 | — |
| Price / sales | 9.9 | 90.1 | 13.2 | — | 7.4 | 3.7 | — | 13.8 | 8.3 | 193.4 |
| Price / book | 0.9 | 0.9 | 0.8 | 0.9 | 1.0 | 0.9 | 0.9 | 0.9 | 1.0 | 1.0 |
| EV / sales | 9.9 | 90.1 | 13.2 | — | 7.5 | 3.7 | — | 13.8 | 8.3 | 193.4 |
| EV / EBITDA | 10.0 | — | 13.6 | — | 7.3 | 3.7 | — | 13.3 | 8.1 | — |
| Earnings yield | 10.0% | 19.1% | 7.3% | −23.7% | 13.4% | 26.7% | −18.5% | 7.1% | 11.8% | −6.0% |
| Share price at fiscal year-end | $18.46 | $18.62 | $15.55 | $17.28 | $25.57 | $20.62 | $18.34 | $23.15 | $25.23 | $23.81 |
| Per share | ||||||||||
| Revenue per share | $1.86 | $0.21 | $1.18 | $0.00 | $3.46 | $5.54 | $0.00 | $1.68 | $3.03 | $0.12 |
| Earnings per share | $1.84 | $3.55 | $1.14 | −$4.10 | $3.42 | $5.50 | −$3.39 | $1.64 | $2.98 | −$1.44 |
| Cash per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.06 | $0.04 | $0.00 | $0.16 | $0.00 |
| Book value per share | $20.39 | $20.33 | $18.84 | $19.36 | $25.47 | $24.04 | $20.33 | $25.62 | $26.02 | $24.99 |
| Tangible book value per share | $20.39 | $20.33 | $18.84 | $19.36 | $25.47 | $24.04 | $20.33 | $25.62 | $26.02 | $24.99 |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Debt per share | — | — | — | $0.18 | $0.25 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares outstanding | 53.6M | 52.1M | 49.4M | 47.3M | 45.4M | 43.9M | 42.8M | 42.2M | 40.6M | 39.0M |
| Change in shares outstanding | +2.9% | +5.4% | +4.4% | +4.2% | +3.5% | +2.4% | +1.4% | +3.9% | +4.2% | +4.6% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 9.2% | 18.6% | 6.1% | −18.7% | 14.0% | 25.1% | −14.9% | 6.5% | 11.9% | −5.4% |
| Return on invested capital (ROIC) | 7.2% | −0.0% | 6.1% | −14.7% | 14.0% | 25.1% | −11.8% | 6.5% | 12.0% | −0.5% |
| Return on assets (ROA) | 9.1% | 18.6% | 6.1% | −18.5% | 13.9% | 24.9% | −14.8% | 6.4% | 11.7% | −5.3% |
| Return on tangible assets | 9.0% | 17.4% | 6.0% | −21.0% | 13.2% | 22.8% | −16.6% | 6.4% | 11.4% | −5.5% |
| Financial health | ||||||||||
| Total debt | — | — | — | $8.5M | $11.3M | $31,402 | $0 | $0 | $0 | $0 |
| Cash & short-term investments | $59 | $56 | $214 | $792 | $935 | $2.5M | $1.7M | $927 | $6.5M | $883 |
| Net debt | −$59 | −$56 | −$214 | $8.5M | $11.3M | −$2.4M | −$1.7M | −$927 | −$6.5M | −$883 |
| Debt / equity | — | — | — | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt / assets | — | — | — | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net debt / EBITDA | −0.00 | — | −0.00 | — | 0.07 | −0.01 | — | −0.00 | −0.05 | — |
| Current ratio | 2.15 | 0.43 | 34.51 | 4.40 | 0.79 | 6.26 | 3.95 | 4.96 | 3.40 | 1.67 |
| Quick ratio | 2.15 | 0.43 | 34.51 | −0.87 | −0.72 | 6.26 | 0.11 | 4.96 | 3.40 | 1.67 |
| Interest coverage | — | — | — | — | — | — | — | — | — | -0.1 |
| Working capital | $1.4M | −$791,217 | $38.5M | $33.0M | −$3.2M | $5.7M | $20.4M | $14.9M | $23.4M | $23.5M |
| Invested capital | $1.09B | $1.06B | $931.3M | $925.1M | $1.17B | $1.05B | $869.2M | $1.08B | $1.05B | $974.8M |
| Tangible asset value | $1.09B | $1.06B | $931.3M | $916.6M | $1.16B | $1.05B | $870.8M | $1.08B | $1.06B | $974.8M |
| Net current asset value | −$814,969 | −$791,218 | $38.5M | $33.0M | −$3.2M | $5.7M | $20.4M | $14.9M | $23.4M | $23.5M |
| Graham number | $29.05 | $40.28 | $21.98 | — | $44.24 | $54.53 | — | $30.74 | $41.79 | — |
| Graham net-net per share | −$0.03 | −$0.02 | $0.08 | $0.38 | −$0.02 | $0.10 | $0.35 | −$0.08 | −$0.08 | −$0.71 |
| Capital allocation | ||||||||||
| Capex / revenue | 0.0% | 0.0% | 0.0% | — | 0.0% | 0.0% | — | 0.0% | 0.0% | 0.0% |
| Capex / depreciation | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| R&D / revenue | — | — | 0.0% | — | 0.0% | 0.0% | — | — | — | — |
| SG&A / revenue | 1.1% | 102.0% | 2.1% | — | 0.8% | 0.5% | — | 1.7% | 1.0% | 230.9% |
| Efficiency | ||||||||||
| Days sales outstanding | 5.5 | 124.6 | 30.5 | — | 9.7 | 10.0 | — | 1.7 | 14.5 | 437.7 |
| Days of inventory on hand | — | — | 856.9 | 1,208.9 | 734.7 | — | 1,008.2 | — | — | — |
| Days payables outstanding | — | — | — | — | — | — | 162.5 | 204.4 | 785.3 | 825.1 |
| Cash conversion cycle (days) | — | — | — | — | — | — | — | -202.8 | -770.8 | -387.4 |
| Receivables turnover | 65.79 | 2.93 | 11.96 | 0.00 | 37.55 | 36.42 | 0.00 | 220.53 | 25.14 | 0.83 |
| Payables turnover | 0.00 | — | — | — | — | — | 2.25 | 1.79 | 0.46 | 0.44 |
| Inventory turnover | — | — | 0.43 | 0.30 | 0.50 | — | 0.36 | — | — | — |
| Asset turnover | 0.09 | 0.01 | 0.06 | 0.00 | 0.14 | 0.25 | 0.00 | 0.07 | 0.12 | 0.00 |
| Average receivables | $1.5M | $3.7M | $4.9M | $3.5M | $4.2M | $6.7M | $4.7M | $321,819 | $4.9M | $5.8M |
| Average payables | $1.2M | — | — | — | — | — | $4.3M | $5.6M | $21.2M | $23.0M |
| Average inventory | — | — | $25.6M | $37.4M | $23.7M | — | $26.6M | — | — | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from HQH's annual financial statements (latest annual report filed September 30, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
HQH valuation and financial ratios
At the end of fiscal 2025 (September 30, 2025), Tekla Healthcare Investors traded at 10.0 times earnings, against a 10-year median of 8.5. Based on the latest twelve months, the trailing P/E is 4.2. Tekla Healthcare Investors earned a return on equity of 9.2% and a return on invested capital of 7.2% in fiscal 2025. The share count rose 37.5% from 39.0M to 53.6M over 9 years.
See the HQH income statement, the HQH chart for price history, or the HQH stock overview for the latest quote and news.
HQH key metrics FAQ
What is Tekla Healthcare Investors's P/E ratio?
Tekla Healthcare Investors's trailing P/E ratio is 4.2 based on the last twelve months of earnings (as of October 18, 2026). At the end of fiscal 2025 it was 10.0, compared with a 10-year median of 8.5.
What is Tekla Healthcare Investors's EV/EBITDA?
Tekla Healthcare Investors's enterprise value was 10.0 times EBITDA at the end of fiscal 2025 (enterprise value $990.1 million, EBITDA $98.6 million).
What is Tekla Healthcare Investors's return on equity?
Tekla Healthcare Investors's return on equity (ROE) was 9.2% in fiscal 2025: net income of $98.6 million on average shareholders' equity of $1.1 billion.
What is Tekla Healthcare Investors's ROIC?
Tekla Healthcare Investors's return on invested capital was 7.2% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
What is Tekla Healthcare Investors's current ratio?
Tekla Healthcare Investors's current ratio was 2.15 at the end of fiscal 2025: current assets were 2.15 times current liabilities.